US FDA OK's Renal Solutions' Allient sorbent haemodialysis system:
This article was originally published in Clinica
Renal Solutions has been given the green light to sell in the US, its Allient sorbent haemodialysis system for chronic and acute haemodialysis applications. The system provides short, standard or extended duration haemodialysis therapy using just 1.5 gallons of normal drinking water, the company said, allowing patients to undergo increased cumulative dialysis dose without the need for an independent water system or large volumes of sterile fluid. Renal Solutions, based in Warrendale, Pennsylvania, has also received an investigational device exemption to begin a home patient clinical safety trial of the system.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.